Recent non-hydroxamate matrix metalloproteinase inhibitors

Bibliography

• HODGSON J: Remodeling MMPIs Biotechnology (1995) 13:554–557.
   PubMedGoogle Scholar
• DOHERTY TM, ASOTRA K, PEI DQ et al.: Therapeutic developments in matrix metalloproteinase inhibition. Expert Opin. Ther. Patents (2002) 12:665–707.
   Web of Science ®Google Scholar
• ••An excellent comprehensive review thatdescribes the MMPs in detail and the clinical rationale for the exploitation of their action.
   Google Scholar
• WHIFIAKER M, FLOYD CD, BROWN P, GEARING AJ: Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. (1999) 99:2735–2776.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review of MMPs and theinhibitors developed until the date of its publication.
   Google Scholar
• WOJTOWICZ-PRAGA S: Clinical potential of matrix metalloproteinase inhibitors. Drugs R D. (1999) 1:117–129.
   PubMedGoogle Scholar
• SKILES JW, GONNELLA NC, JENG AY: The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr. Med. Chem. (2001) 8:425–474.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive and useful review of MMPs and the inhibitors developed that includes 3D-structures of human MMPs with and without bound inhibitors determined by X-ray crystallography or by NMR and other tabulated data until the date of publication.
   Google Scholar
• SKILES JW, GONNELLA NC, JENG AY: The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. Curr. Med. Chem. (2004) 11:2911–2977.
   PubMed Web of Science ®Google Scholar
• ••An updated version of the previousreference. A very detailed, useful and most recent review of the area.
   Google Scholar
• HIDALGO M, ECKHARDT SG: Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. (2001) 93:178–193.
   PubMed Web of Science ®Google Scholar
• COUSSENS LM, FINGLETON B, MATRISIAN LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (2002) 295:2387–2392.
   PubMed Web of Science ®Google Scholar
• •This article summarises the role of MMPs in cancer and the history of development of MMPIs.
   Google Scholar
• EGEBLAD M, WERB Z: New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer (2002) 2:161–174.
   PubMed Web of Science ®Google Scholar
• •This is an excelent review on the role of MMPs in cancer.
   Google Scholar
• OVERALL C, LOPEZ-OTIN C: Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer (2002) 9:657–672.
   Google Scholar
• •This article analyses the reasons why the pharmaceutical industry has failed in developing MMPI.
   Google Scholar
• CONNELL RD: Patent focus on cancer chemotherapeutics V. Angiogenesis agents: September 2001 - August 2002. Expert Opin. Ther. Patents (2002) 12:1763–1782
   Google Scholar
• ••See also previous reviews I - W.
   Google Scholar
• SKILES JW, MONO VISH LG, JENG AY:Matrix metalloproteinase inhibitors for treatment of cancer. Ann. Rep. Med. Chem. (2000) 35:167–176.
   Web of Science ®Google Scholar
• PAVLAKI M, ZUCKER S: Matrix metalloproteinase inhibitors (MMPIs): The beginning of Phase I or the termination of Phase III clinical trials. Cancer Metastasis Rev. (2003) 22:177–203.
   PubMed Web of Science ®Google Scholar
• •This article describes a new approach to the understanding of the potential roles of future MMPIs.
   Google Scholar
• ZUCKER S, VACIRCA J: Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev. (2004) 23:101–117.
   PubMed Web of Science ®Google Scholar
• JONES LE, HUMPHREYS MJ, CAMPBELL F, NEOPTOLEMOS JP, BOYD MT: Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin. Cancer Res. (2004) 10:2832–2845.
   PubMed Web of Science ®Google Scholar
• DAHLBERG L, BILLINGHURST RC, MANNER P et al.: Selective enhancement of collagenase-mediated cleavage of resident Type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1). Arthritis Rheum. (2000) 43:673–682.
   PubMed Web of Science ®Google Scholar
• HENROTIN Y, SANCHEZ C, REGINSTER JY: The inhibition of metalloproteinases to treat osteoarthritis: reality and new perspectives. Expert Opin. Ther. Patents (2002) 12:29–43.
   Web of Science ®Google Scholar
• SHIRE MG, MULLER GW: TNF-a inhibitors and rheumatoid arthritis. Expert Opin. Ther. Patents (1998) 8:531–544.
   Web of Science ®Google Scholar
• ISHIGURO N, ITO T, OGUCHI T et aL: Relationships of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover and inflammation as revealed by analyses of synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum. (2001) 44:2503–2511.
   PubMedGoogle Scholar
• CHU Q, LOPEZ M, HAYASHI K et aL: Elevation of collagenase generated Type II collagen neoepitope and proteoglycan epitopes in synovial fluid following induction of joint instability in the dog. Osteoarth. CartiL (2002) 10:662–669.
   PubMed Web of Science ®Google Scholar
• IKEDA U, SHIMADA K: Matrix metalloproteinases and coronary artery diseases. Clin. CardioL (2003) 26:55–59.
   PubMed Web of Science ®Google Scholar
• PETERSON JT: Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail. Rev. (2004) 9:63–79.
   PubMed Web of Science ®Google Scholar
• •This article focuses on some of the lessons to be learned from the failure of so many MMP inhibitors across so many indications, and what potential exists in the future for MMP inhibitors.
   Google Scholar
• LINDSEY ML: MMP Induction and inhibition in myocardial infarction. Heart Fail. Rev. (2004) 9:7–19.
   PubMed Web of Science ®Google Scholar
• DONNELLY LE, ROGERS DF: Antiproteases and retinoids for treatment of chronic obstructive pulmonary disease. Expert Opin. Ther. Patents (2003) 13:1345–1372.
   Web of Science ®Google Scholar
• •This article describes recent patent applications of different structural classes of rotease inhibitors and retinoid compounds that may be of benefit in COPD. MMP inhibitors is only one of these classes.
   Google Scholar
• SUZUKI R, MIYAZAKI Y, TAKAGI K, TORII K, TANIGUCHI H: Matrix metalloproteinases in the pathogenesis of asthma and COPD: implications for therapy. Treat. Respir. Med. (2004) 3:17–27.
   PubMedGoogle Scholar
• •This article describes current views on the role of MMPs in the pathogenesis of bronchial asthma and of COPD.
   Google Scholar
• GOLUB LM, MCNAMARA TF, RYAN ME et al.: Adjunctive treatment with subantimicrobial doses of doxycycline: effects on gingival fluid collagenase activity and attachment loss in adult periodontitis. J. Clin. PeriodontoL (2001) 28:146–156.
   PubMed Web of Science ®Google Scholar
• LEE HM, CIANCIO SG, TUTER G, RYAN ME, KOMAROFF E, GOLUB LM: Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis patients is enhanced when combined with a non-steroidal anti-inflammatory drug. J. Periodontol. (2004) 75:453–463.
   PubMed Web of Science ®Google Scholar
• ACHARYA MR, VENITZ J, FIGG WD, SPARREBOOM k Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resist. Updat. (2004) 7:195–208.
   PubMed Web of Science ®Google Scholar
• MATTHEWS BW: Structural basis of theaction of thermolysin and related zinc peptidases. Acc. Chem. Res. (1988) 21:333–340.
   Web of Science ®Google Scholar
• PIKUL S, OHLER NE, CISZEWSKI G et al.: Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases. J. Med. Chem. (2001) 44:2499–2502.
   PubMed Web of Science ®Google Scholar
• WANG X, CHOE Y, CRAIK CS, ELLMAN JA: Design and synthesis of novel inhibitors of gelatinase B. Bioorg. Med. Chem. Lett. (2002) 12:2201–2204.
   PubMed Web of Science ®Google Scholar
• AUGE F, HORNEBECK W, DECARME M, LARONZE J-Y: Improved gelatinase A selectivity by novel zinc binding groups containing galardin derivatives. Bioorg. Med. Chem. Lett. (2003) 13:1783–1786.
   PubMed Web of Science ®Google Scholar
• FARKAS E, KATZ Y, BHUSARE S et al.:Carbamoylphosphonate based matrix metalloproteinase (MMP) inhibitor metal complexes - solution studies and stability constants, towards a zinc selective binding group. J. Biol. Inorg Chem. (2004) 9:307–315.
   PubMed Web of Science ®Google Scholar
• MOORE WM, SPILBURG CA: Purification of human collagenases with a hydroxamic acid affinity column. Biochemistry (1986) 25:5189–5195.
   PubMed Web of Science ®Google Scholar
• TURBANTI L, CERBAI G, DI BUGNO C et al.: 1,2-Cyclomethylenecarboxylic monoamide hydroxamic derivatives. A novel class of non-amino acid angiotensin converting enzyme inhibitors./ Med. Chem. (1993) 36:699–707.
   Google Scholar
• MATTER H, SCHUDOK M: Recent advances in the design of matrix metalloprotease inhibitors. Curr. Opin. Drug Discov. DeveL (2004) 7:513–535.
   PubMed Web of Science ®Google Scholar
• FUJISAWA T, ODAKE S, OGAWA Y, YASUDA J, MORITA Y, MORIKAWA T: Design and synthesis of sulfur based inhibitors of matrix metalloproteinase-1. Chem. Pharm. BulL (2002) 50:239–252.
   PubMed Web of Science ®Google Scholar
• FUJISAWA T, KATAKURA S, ODAKE S et al.: Design and synthesis of carboxylate inhibitors for matrix metalloproteinases. Chem. Pharm. BulL (2001) 49:1272–1279.
   PubMed Web of Science ®Google Scholar
• TULLIS JS, LAUFERSWEILER MJ, VANRENS JC et al.: The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold. Bioorg. Med. Chem. Lett. (2001) 11:1975–1979.
   PubMed Web of Science ®Google Scholar
• LE DIGUARHER T, CHOLLET AM, BERTRAND M et aL: Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors. J. Med. Chem. (2003) 46:3840–3852.
   PubMed Web of Science ®Google Scholar
• DELBECQ F, CORDONNIER G, POMMERY N, BARBRY D, HENICHART JP: New heteroaryl benzenesulphonamides as matrix metalloproteinase inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:1119–1121.
   PubMedGoogle Scholar
• MATZIARI M, BEAU F, CUNIASSE P, DIVE V YIOTAKIS A: Evaluation of P V-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11. J. Med. Chem. (2004) 47:325–336.
   PubMed Web of Science ®Google Scholar
• FOLEY LH, PALERMO R, DUNTEN P, WANG P: Novel 5,5-disubstituted pyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg. Med. Chem. Lett. (2001) 11:969–972.
   PubMed Web of Science ®Google Scholar
• GRAMS F, BRANDSTETTER H, D'ALO S et al.: Pyrimidine-2,4,6-triones: a new effective and selective class of matrix metalloproteinase inhibitors. Biol. Chem. (2001) 382:1277–1285.
   Google Scholar
• BRANDSTETTER H, GRAMS F, GLITZI D et al.: The 1.8 A crystal structure of a matrix metalloproteinase 8-barbiturate inhibitor complex reveals a previously unobserved mechanism for collagenase substrate recognition. J. Biol Chem. (2001) 276:17405–17412.
   Google Scholar
• MAQUOI E, SOUNNI NE, DEVY L et al.: Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor. Clin. Cancer Res. (2004) 10:4038–4047.
   PubMed Web of Science ®Google Scholar
• SCHRODER J, HENKE A, WENZEL H et al.: Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold. J. Med. Chem. (2001) 44:3231–3243.
   PubMed Web of Science ®Google Scholar
• COOK GR, MANIVANNAN E, UNDERDAHL T, LUKACOVA V, ZHANG Y, BALAZ S: Synthesis and evaluation of novel oxazoline MMP inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:4935–4939.
   PubMedGoogle Scholar
• CAINELLI G, GALLETTI P, GARBISA S,GIACOMINI D, SARTOR L, QUINTAVALLA A: 4-Alkylideneazetidin-2-ones: novel inhibitors of leukocyte elastase and gelatinase. Bioorg. Med. Chem. (2003) 11:5391–5399.
   PubMed Web of Science ®Google Scholar
• BREUER E, SALOMON CJ, KATZ Y et al.: Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids. J. Med. Chem. (2004) 47:2826–2832.
   Google Scholar
• BREUER E, KATZ Y, HADAR R, REICH R: Carbamoylphosphonate MMP inhibitors 4. The influence of chirality and geometrical isomerism on the potency and selectivity of inhibition. Tetrahedron Asymmetry (2004) 15:2415–2420.
   Google Scholar
• REICH R, KATZ Y, HADAR R, BREUER E: Carbamoylphosphonate MMP inhibitors 3. In vivo evaluation of cyclopentylcarbamoylphosphonic acid, CPCPA, in experimental metastasis and angiogenesis. Clin. Cancer Res. in press.
   Google Scholar
• BROWN S, BERNARDO MM, LI Z-H et al.: Potent and selective mechanism-based inhibition of gelatinases. J. Am. Chem. Soc. (2000) 122:6799–6800.
   Web of Science ®Google Scholar
• PERGAMENT I, REICH R, SREBNIK M: Novel matrix metallo-proteinase (MMP-2) phosphonoboronate inhibitors. Bioorg. Med. Chem. Lett. (2002) 12:1215–1218.
   PubMed Web of Science ®Google Scholar
• QUNTAR A, BAUM 0, REICH R, SREBNIK M: Recently synthesized class of vinylphosphonates as potent matrix metalloproteinase (MMP-2) inhibitors. Arch. Pharm. Pharm. Med. Chem. (2004) 337:76–80.
   PubMed Web of Science ®Google Scholar
• ABU ALI H, BERKOVITZ R, REICH R, SREBNIK M: Matrix metallo-proteinase (MMP-2) organoboronate inhibitors. Arch. Pharm. Pharm. Med. Chem. (2004) 37:183–187.
   Google Scholar
• PUERTA DT, LEWIS JA, COHEN SM: New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups. J. Am. Chem. Soc. (2004) 126:8388–8389.
   PubMed Web of Science ®Google Scholar
• FUJITA M, NAKAO Y, MATSUNAGA S et al.: Ageladine A: an antiangiogenic matrix metalloproteinase inhibitor from the marine sponge Agelas nakamurai. J. Am. Chem. Soc. (2003) 125:15700–15701.
   PubMed Web of Science ®Google Scholar
• MORALES R, PERRIER S, FLORENT JM et al.: Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12. j MoL Biol. (2004) 341:1063–1076.
   PubMed Web of Science ®Google Scholar
• ENDE C, GEBHART R: Inhibition of matrix metalloproteinase-2 and -9 activities by selected flavanoids. Planta Med. (2004) 70:1006–1008.
   PubMed Web of Science ®Google Scholar
• PATANI Gk LAVOIE EJ: Bioisosterism: a rational approach in drug design. Chem. Rev. (1996) 96:3147–3176.
   PubMed Web of Science ®Google Scholar
• FOLGUERAS AR, PENDAS AM, SANCHEZ LM, LOPEZ-OTIN C: Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int. J. Dev. Biol. (2004) 48:411–424.
   PubMed Web of Science ®Google Scholar
• •A recent review summarising the literature including the complexity of the phenomena (favourable and unfavourable) that may result from the action of broad spectrum MMPIs.
   Google Scholar
• BROWNER MF, SMITH WW, CASTELHANO AL: Matrilysin-inhibitor complexes: common themes among metalloproteases. Biochemistry (1995) 34:6602–6610.
   PubMed Web of Science ®Google Scholar
• O'BRIEN EC, FARKAS E, GIL MJ, FITZGERALD D, CASTINERAS A, NOLAN KB: Metal complexes of salicylhydroxamic acid (H2Sha), anthranilic hydroxamic acid and benzohydroxamic acid, crystal and molecular structure of Cu(Phen)2(C1)1- Clph2sha, a model for a peroxidase inhibitor complex. J. Inorg. Biochem. (2000) 79:47–51.
   PubMed Web of Science ®Google Scholar
• FURIA TE: Sequestrants in food (chapter 6). In: CRC Handbook of Food Additives 2"a Ed Furia TE (Ed.) (1972):271–294.
   Google Scholar
• CANNAN, RK, KIBRICK A: Complex formation between carboxylic acids and divalent metal cations. J. Am. Chem. Soc. (1938) 60:2314–2320.
   Google Scholar
• Textbook of Biochemistry 4th Ed Devlin TM (Ed.) Wiley-Liss, NY, USA (1997):151–152.
   Google Scholar
• GARDNER CR, WALSH CT, ALMARSSON 0: Drugs as materials: valuing physical form in drug discovery. Nat. Rev. Drug Dis. (2004) 3:926–934.
   PubMed Web of Science ®Google Scholar